Patent Estate
ENDECE’s platform of proprietary therapeutic agents with novel mechanisms of action against diseases has been discovered internally and is owned by the Company.
ENDECE’s platform of proprietary therapeutic agents with novel mechanisms of action against diseases has been discovered internally and is owned by the Company.
Home
Corporate
· About Endece
· History
· Corporate Compliance
· Corporate Strategy
· Management
· Scientific Advisory Board
· Network
“Previous experience taught me the hard way that one should not attempt to start a business, especially in science, unless you are working with only the very best of the best.”
Our business collaborative model includes supportive investors, experienced management team and respected advisors all focused on the discovery and development of new drug concepts; EN-DE-CE.
“Our recent discovery, that ENDECE’s proprietary library of structurally related small molecules can dramatically influence the outcome of estrogen receptor activation, is leading to new ways to treat human diseases including cancer.”
“The human body regulates it’s self via biological pathways. The ENDECE concept is to modulate these naturally occurring pathways to control and stop the progression of disease.”
“Our data suggests that ENDECE’s lead drug, NDC-1308, effectively activates biological pathways that normally kill damaged cells but are evaded by tumor cells.”
“Total confidence in our novel approach to rational drug design and focused early development utilizing the best talent and latest technology we can find is our strategy for success.”
“ENDECE’s drug discovery efforts that started with modeling nuclear receptor ligand binding domains have led to an in-house library of new and proprietary compounds.”
“Preclinical efforts that characterized NDC-1308’s mechanism of action at the molecular level will serve as a bridge to clinical studies and potentially reveal relevant biomarkers.”
“We are ecstatic with our success in harnessing the biological activities directed by estrogen receptors in new ways to treat human diseases including cancer.”
“Preclinical studies, performed by our network of expert collaborators, have enabled insight into NDC-1308’s mechanism of action at the molecular level along with proof of principal in established animal models.”
“ENDECE’s drug discovery efforts that started with modeling nuclear receptor ligand binding domains have led to an in-house library of new and proprietary compounds.”
“What appealed to me was that it was such a novel, different, creative strategy. Either this is going to be a total bust or something very interesting.”
“ENDECE’s leaders have years of experience building new high tech businesses which I expect will be hugely successful.”
ENDECE
1001 W. Glen Oaks Lane
Suite 105B
Mequon, WI 53092
Ph: 262-240-9690
Fax: 262-240-9693